Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 2
2003 2
2004 1
2006 1
2007 1
2009 2
2010 2
2011 3
2012 3
2013 1
2014 2
2015 6
2016 13
2017 15
2018 23
2019 19
2020 20
2021 3
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 33419945

102 results
Results by year
Filters applied: . Clear all
Page 1
Evaluation of safety and dosimetry of 177Lu DOTA-ZOL for therapy of bone metastases.
Fernandez R, Eppard E, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Ceballos M, Ribbeck J, Kluge A, Roesch F, Meckel M, Zhernosekov K, Kramer V, Amaral H. Fernandez R, et al. J Nucl Med. 2021 Jan 8:jnumed.120.255851. doi: 10.2967/jnumed.120.255851. Online ahead of print. J Nucl Med. 2021. PMID: 33419945
Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results.
Khawar A, Eppard E, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. Khawar A, et al. EJNMMI Res. 2019 Nov 28;9(1):102. doi: 10.1186/s13550-019-0566-x. EJNMMI Res. 2019. PMID: 31781962 Free PMC article.
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.
Kurth J, Krause BJ, Schwarzenböck SM, Bergner C, Hakenberg OW, Heuschkel M. Kurth J, et al. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):123-135. doi: 10.1007/s00259-019-04504-3. Epub 2019 Sep 3. Eur J Nucl Med Mol Imaging. 2020. PMID: 31482426
Preliminary results of biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases.
Khawar A, Eppard E, Roesch F, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Gaertner FC, Essler M, Bundschuh RA. Khawar A, et al. Ann Nucl Med. 2019 Jun;33(6):404-413. doi: 10.1007/s12149-019-01348-7. Epub 2019 Mar 15. Ann Nucl Med. 2019. PMID: 30877560
Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Böning G. Delker A, et al. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51. doi: 10.1007/s00259-015-3174-7. Epub 2015 Aug 29. Eur J Nucl Med Mol Imaging. 2016. PMID: 26318602
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC.
Kramer V, Fernández R, Lehnert W, Jiménez-Franco LD, Soza-Ried C, Eppard E, Ceballos M, Meckel M, Benešová M, Umbricht CA, Kluge A, Schibli R, Zhernosekov K, Amaral H, Müller C. Kramer V, et al. Eur J Nucl Med Mol Imaging. 2020 Sep 19. doi: 10.1007/s00259-020-05022-3. Online ahead of print. Eur J Nucl Med Mol Imaging. 2020. PMID: 32949253
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.
Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Zhang J, et al. J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653971 Free PMC article. Clinical Trial.
Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.
Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2020 May 5. doi: 10.1089/cbr.2020.3640. Online ahead of print. Cancer Biother Radiopharm. 2020. PMID: 32379495
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Meckel M, Bergmann R, Miederer M, Roesch F. Meckel M, et al. EJNMMI Radiopharm Chem. 2017;1(1):14. doi: 10.1186/s41181-016-0017-1. Epub 2016 Sep 23. EJNMMI Radiopharm Chem. 2017. PMID: 29564390 Free PMC article.
[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results.
Yadav MP, Ballal S, Meckel M, Roesch F, Bal C. Yadav MP, et al. EJNMMI Res. 2020 Oct 28;10(1):130. doi: 10.1186/s13550-020-00709-y. EJNMMI Res. 2020. PMID: 33113035 Free PMC article.
102 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page